08:14 AM EST, 02/17/2026 (MT Newswires) -- Pfizer ( PFE ) on Tuesday reported positive results from a trial evaluating Braftovi in combination with cetuximab and Folfiri in patients with previously untreated metastatic colorectal cancer.

The regimen showed a "statistically significant and clinically meaningful" improvement in progression-free survival, a key secondary endpoint, Pfizer ( PFE ) said. Overall survival, a descriptive secondary endpoint, also showed "clinically meaningful prolonged improvement," the drug maker said.

Detailed results will be shared with the US Food and Drug Administration to support the potential approval of the drug combination, Pfizer ( PFE ) said.